On the stock market since 2014, it operates in the world of health and science. It has 2 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 6% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Bets Against the Stock: The number of investors betting on a fall stands out.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The company sells $6.5M a year; the problem isn’t sales — it’s costs running above that number.
There is $9.9M in the vault; even if every debt were paid off, $9.9M would remain.
Over the last 12 months, company executives reported 1 buy and 0 sells. Management buying with its own money is usually read as a good sign.
A loss of $2.8M against $6.5M in annual sales.
The stock sits at $0.0001. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
On our five-subject report card, GBIM sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: GBIM is a small company that closed last year at a loss. The road back to profit runs through spending discipline.